Please upgrade your browser.
New evidence suggests that three-dimensional pathological tumor volume (TV) provides additional prognostic information in renal cell carcinoma (RCC) to that provided by tumor size alone.
...watch a video about our peer review process & apply for a YIA.
Certain nanoparticles (NP) emit heat energy when excited by near-infrared (NIR) laser energy. We determined efficacy of a novel nanoparticle to induce hyperthermic cellular death of renal cell carcinoma in vitro.
At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance.
Osteosarcoma cells expressing high levels of VEGFR1...
Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line RCC Treatment
The combination of gemcitabine plus capecitabine and sunitinib (GCS) shows activity in metastatic renal cell carcinoma (mRCC).
mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors.
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that have a pivotal role in the post-transcriptional regulation of gene expression and their misregulation is common in different types of cancer.
Anti-tumor effect of ribavirin in combination with interferon-alpha on renal cell carcinoma cell lines in vitro
Ribavirin is an anti-viral drug; however, recent data suggest that it may also be effective in cancer therapy.
The vascular endothelial growth factor (VEGF) pathway blockers and mammalian target of rapamycin (mTOR) inhibitors have dramatically improved the treatment options and outcome for patients with advanced renal cell carcinoma (RCC).
|Powered by NeonCRM|